Building Translational Models Beyond Bleomycin that Accurately Determine Efficacy, MOA & Drug-Drug Interactions, Deciphering Necessary Changes to Clinical Protocols & Exploring Novel Mechanisms to Move Beyond Slowing FVC Decline to Improving Patients' Quality of Life
For a decade, the IPF Summit has been the go-to forum uniting stakeholders across the pulmonary fibrosis landscape, and this year, the conversation has never been more critical.
As a wave of late-stage successes reshapes the treatment landscape, IPF has entered a new era, even more complex than before. With multiple therapies emerging, evolving standards of care, and increasing pressure to demonstrate differentiated value, the question is no longer if we can develop effective treatments, but how to do so smarter, faster, and with greater impact for patients.
The 10th IPF Summit is the only end-to-end, industry-led meeting designed to tackle this head-on. Bringing together experts across discovery, translational science, and clinical development, the summit offers a uniquely integrated view of the challenges, and opportunities, defining the next decade of IPF drug development.
From novel biology and biomarker-driven strategies to next-generation trial design and combination approaches, this is where leaders come to align on what success now looks like.
If you’re looking to stay competitive in a rapidly evolving field, this is the room you need to be in.
Here’s Why Your Colleagues Love the Intimacy of the Summit:
A small event where many people were able to share in an open conversation rather than just listen to presentations. “The diversity of topics across innovative biology and clinical development in a small setting makes this a unique conference.
Altos Labs
Complete scope of work from concepts to clinical development and possibly approval. Excellent personal interactions with academics and biotechnology company representatives.
JN Nova Pharma Inc.
I truly appreciate the scale of the summit and the diversity of attendees, ranging from small biotech and large pharma to clinicians and academics. This diversity creates a valuable opportunity for cross-disciplinary learning, identification of gaps, and alignment on the trajectory of IPS/ILD research. Additionally, it fosters collaborations among experts from various fields.
Takeda
Explore the Full Event Guide
- Get the Full Strategic Picture in One Place: Access the complete agenda, speaker faculty, and session breakdown to clearly map where your priorities align
- Explore What’s New for 2026: Discover the latest agenda additions, tracks, and emerging topics reflecting how the IPF landscape has evolved over the past year
- Dive Deeper into Key Case Studies & Data Highlights: Preview the real-world examples, clinical insights, and cutting-edge research shaping discussions onsite
- Understand How the Industry is Shifting: Gain a clearer view of the trends, challenges, and opportunities redefining IPF drug development, and how the program is built to address them
- Easily Share & Align Your Team: Download and circulate internally to ensure the right stakeholders attend and maximize value across your organization
Official Partners
Attending Companies Include
Explore the Brand-New Agenda
Hear the latest industry updates and gain exclusive insights during our packed discussion-led agenda.
Partner With the IPF Summit
Position yourself alongside other leading solution providers to ensure your brand is directly in front of IPF, ILD & PPF decision makers.
Join An Intimate Community Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during dedicated networking sessions.